The following workshop will be hosted by Thermo Fisher Scientific during the EMBL Conference: Cancer Genomics:
Pioneering the Path to Precision Oncology
|Date: Monday, November 6th, from 1:00 to 1:45 p.m.|
Venue: EMBL Advanced Training Centre, Flex Lab A+B
The promise of precision medicine: NGS has quickly emerged as a helpful tool to study multiple genes and mutation types in a single assay, thus preserving precious samples and significantly reducing time. In 2015, the National Cancer Institute and three other leading cancer centres initiated the NCI-MATCH clinical trial, which analyses an individual’s tumor tissue using Next Generation Sequencing (NGS) to screen for relevant mutations that can be tied to targeted therapies. In this talk we will present the first results of the NCI MATCH trial and how next generation sequencing can innovate Liquid Biopsy and Immuno-Therapy research.
All conference participants have received an email with a registration link. Registration will be possible until Thursday, 26 October 2017.
Participation in the workshop is first come - first served.